Osteocel is a premier allograft cellular bone matrix designed to mimic the biological profile of autograft. It is comprised of cancellous bone rich in viable cells, combined with demineralized bone matrix from the same donor. The retained cells are naturally adherent to the surface of the cancellous bone and consist of mesenchymal stem cells (MSCs), osteoprogenitors, osteoblasts and other cells along the osteogenic lineage.
All donors for Osteocel are qualified in a stringent, multistep screening and testing process in accordance with Food and Drug Administration (FDA) and American Association of Tissue Banks (AATB) regulations, with the entire Osteocel allograft processing method taking place within 96 hours.
All donors for Osteocel are qualified in a stringent, multistep screening and testing process in accordance with Food and Drug Administration (FDA) and American Association of Tissue Banks (AATB) regulations, with the entire Osteocel allograft processing method taking place within 96 hours.
All donors for Osteocel are qualified in a stringent, multistep screening and testing process in accordance with Food and Drug Administration (FDA) and American Association of Tissue Banks (AATB) regulations, with the entire Osteocel allograft processing method taking place within 96 hours.
MSCs are part of the native cancellous bone matrix (endogenous to the bone)—the cells are not cultured or expanded. Osteocel contains physiologic levels of bone morphogenic proteins (BMPs)5 from the DBM—no dosing concerns. 1cc of Osteocel has similar numbers of MSCs as 45 cc of unconcentrated BMA in age-matched patients.6
MSCs are part of the native cancellous bone matrix (endogenous to the bone)—the cells are not cultured or expanded. Osteocel contains physiologic levels of bone morphogenic proteins (BMPs)5 from the DBM—no dosing concerns. 1cc of Osteocel has similar numbers of MSCs as 45 cc of unconcentrated BMA in age-matched patients.6
MSCs are part of the native cancellous bone matrix (endogenous to the bone)—the cells are not cultured or expanded. Osteocel contains physiologic levels of bone morphogenic proteins (BMPs)5 from the DBM—no dosing concerns. 1cc of Osteocel has similar numbers of MSCs as 45 cc of unconcentrated BMA in age-matched patients.6
Osteocel Plus is an advanced allograft cellular bone matrix that retains its native bone-forming cells, including mesenchymal stem cells (MSCs) and osteoprogenitors. Osteocel is intended for the repair, replacement, and reconstruction of skeletal defects. Osteocel Plus is our original allograft cellular bone matrix and Osteocel Pro is our latest allograft cellular bone matrix with improved handling, simplified product preparation, and high graft density that allows for a more complete fill of the fusion site.
Osteocel Plus is an advanced allograft cellular bone matrix that retains its native bone-forming cells, including mesenchymal stem cells (MSCs) and osteoprogenitors. Osteocel is intended for the repair, replacement, and reconstruction of skeletal defects. Osteocel Plus is our original allograft cellular bone matrix and Osteocel Pro is our latest allograft cellular bone matrix with improved handling, simplified product preparation, and high graft density that allows for a more complete fill of the fusion site.
1. Eastlack RK, Garfin SR, Brown CR, et al. Osteocel Plus cellular allograft in anterior cervical discectomy and fusion (ACDF): Evaluation of clinical and radiographic outcomes from a prospective multi-center study. Spine 2014; 39(22):E1331-37.
2. Tohmeh AG, Watson B, Tohmeh M, et al. Allograft cellular bone matrix in extreme lateral interbody fusion: preliminary radiographic and clinical outcomes. Sci World J 2012; 2012: 263637.
3. Ammerman JM, Libricz J, Ammerman MD. The role of Osteocel Plus as a fusion substrate in minimally invasive instrumented transforaminal lumbar interbody fusion. Clin Neurol Neurosurg 2013;115(7):991-4.
4. Kerr EJ, Jawahar A, Wooten T, et al. The use of osteo-conductive stem-cells allograft in lumbar interbody fusion procedures: an alternative to recombinant human bone morphogenetic protein. J Surg Ortho Adv 2011;20(3):193-197.
5. Williams G, Mosely T. Osteoinductivity of Allograft Cellular Bone Matrix. 28th NASS Annual Meeting 2013. New Orleans, LA, USA.
6. Baboolal TG, Boxall SA, El-Sherbiny Y, et al. Multipotential stromal cell abundance in cellular bone allograft: comparison with fresh age-matched iliac crest bone and bone marrow aspirate. Regen Med 2014;9(5):593-607.
Osteocel (Allograft Cellular Bone Matrix) HCT/P is a formulation of cryopreserved viable cancellous matrix and ground demineralized bone matrix. The native cell population retained as a result of proprietary tissue processing includes cells of mesenchymal lineage differentiating towards bone-forming cells. This product is an allogeneic bone graft substitute intended for homologous use in the repair, replacement, or reconstruction of musculoskeletal defects. Contraindications include: Allergies to any of the processing agents listed under the Tissue Processing section of the instructions for use, use in immune compromised patients, and/or stand-alone use in load-bearing applications. Please refer to the Osteocel instructions for use for complete important safety information, which can be found on https://www.nuvasive.com/resources/electronic-ifu-information/